<DOC>
	<DOCNO>NCT00045747</DOCNO>
	<brief_summary>RATIONALE : UCN-01 may stop growth tumor cell block enzymes necessary tumor cell growth . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining UCN-01 chemotherapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine UCN-01 fluorouracil treat patient metastatic pancreatic cancer respond treatment gemcitabine .</brief_summary>
	<brief_title>UCN-01 Fluorouracil Treating Patients With Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate , time progression , overall survival patient gemcitabine-refractory metastatic pancreatic cancer treat UCN-01 fluorouracil . - Determine toxicity regimen patient . OUTLINE : Patients receive fluorouracil IV 24 hour day 1 , 8 , 15 , 22 . Patients also receive UCN-01 IV continuously 72 hour ( course 1 ) begin day 2 . In subsequent course , UCN-01 infuse 36 hour . Courses repeat every 28 day absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 12-37 patient accrue study within 3-13 month .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>7-hydroxystaurosporine</mesh_term>
	<mesh_term>Staurosporine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm adenocarcinoma pancreas Progressive disease gemcitabinebased chemotherapy metastatic disease At least 1 unidimensionally measurable metastatic lesion At least 20 mm conventional technique OR At least 10 mm spiral CT scan Primary disease site consider measurable lesion No known brain metastasis PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 01 OR Karnofsky 70100 % Life expectancy More 8 week Hematopoietic WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin normal AST/ALT great 2.5 time upper limit normal Renal Creatinine normal OR Creatinine clearance least 60 mL/min Cardiovascular No symptomatic congestive heart failure No unstable angina pectoris No cardiac tachyarrhythmia Pulmonary No symptomatic chronic obstructive pulmonary disease No pulmonary embolism within past 6 month Other No prior allergic reaction compound similar chemical biological composition UCN01 agent use study No diabetes mellitus uncontrolled insulin oral hypoglycemic agent No uncontrolled concurrent illness No ongoing active infection No psychiatric illness social situation would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception , , 3 month study PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent immunotherapy Chemotherapy See Disease Characteristics More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover No 1 prior chemotherapy regimen metastatic recurrent disease No prior fluorouracil adjuvant inoperable , locally advanced setting ( except radiosensitizer ) No concurrent chemotherapy Endocrine therapy Not specify Radiotherapy More 4 week since prior radiotherapy recover No prior mediastinal irradiation No concurrent radiotherapy Surgery Not specify Other No prior UCN01 cyclindependent kinase inhibitors No concurrent combination antiretroviral therapy HIVpositive patient No concurrent investigational commercial anticancer agent therapies No concurrent anticonvulsant medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2004</verification_date>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>